cyrilzakka/clinical-trials huggingface dataset:
Rapid Medical Donation Programme for Breast Cancer

Treatment of breast cancer has traditionally been based on the primary tumour's features in the breast. Only recently, when cancer returns at other sites, has there been an attempt to biopsy the metastatic disease and change treatments accordingly. A 'repeat biopsy' can be technically difficult, painful and, when possible, only represents a small sample of one of many metastases.

Even when one deposit responds to a new treatment, a neighbouring one may continue to grow. There is an urgent need to characterise all deposits, particularly the lethal ones which progress despite all treatments.

This study will enable the comprehensive analysis of the metastatic process and the evolution of the breast cancer through the course of its treatment. Patients who have consented during life to donate their tissues for molecular analysis will provide the means for such an analysis.

Main aims:

* To comprehensively and systematically examine metastatic breast cancer by its detailed exploratory molecular characterization to elucidate the possible inter- and intratumoural heterogeneity between the primary tumour and the majority of metastatic sites.
* To map the natural history of the metastatic breast cancer process


Eligibility Criteria:
Inclusion Criteria:

* Patients who have completed active treatment (or trials) for metastatic breast cancer.
* Patients referred to either community or the hospital-based palliative care unit from Royal Marsden National Health Service Foundation Trust.

Exclusion Criteria:

* Lack of capacity / inability to give informed consent.
* Diagnosis of alternative cancer within the last 5 years other than resected basal cell skin cancer or cervical intraepithelial neoplasia.
* Patients known to be HIV, Hepatitis B virus or Hepatitis C virus positive on serology .
* Spongiform encephalopathy (known or suspected CJD) .
* Eligibility for or current participation in a clinical trial (excluding palliative care trials)
Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

This study will evaluate the safety and efficacy of intracerebral transplantation of human embryonic stem cells-derived neural precursor cells in patients with Parkinson's Disease.

This study is a Phase I/II, open-label, non randomized clinical trial. The study will enroll 50 patients for cell injection, administering a single dose of neural precursor cells by stereotaxic intra-striatal injection.

Eligibility Criteria:
Inclusion Criteria:

1. Primary Parkinson's disease patients，a history over 5 years，females or males;
2. Cannot effectively control the PD or tolerate the side effects of drugs;
3. Hoehn and Yahr Stage 3 or 4 in the off state at screening
4. Age between 50 and 80 years;
5. Dopamine is effective or once;
6. Sign the informed consent

Exclusion Criteria:

1. Atypical Parkinsonian syndrome or only having tremor syndrome;
2. Having been done pallidotomy, DBS, striatum or extrapyramidal surgery;
3. Subjects are using apomorphine or anticoagulant;
4. Subjects used immunosuppressant or antipsychotic drugs in last 3 months;
5. Subjects used botulinum toxin, phenol, or other drugs for the treatment of dystonia or muscle cramps in last 6 months;
6. During the period of active epilepsy preventing epilepsy with antiepileptic;
7. Coagulant function abnormality or other obviously abnormal laboratory test results;
8. Having skin basal cell carcinoma or cervical cancer and other pre-cancerous lesions;
9. Subject has a history of chronic alcohol or drug abuse ;
10. Pregnancy or lactation;
11. Subjects participated in other clinical trials in recent 3 months;
12. Subject is considered as dementia, a serious mental disorder (depression or mania), and personality or behavioral disorders through cognitive and behavioral test;
13. Cannot cooperate on the research;
14. Severe brain atrophy, or existing brain injury such as cerebral infarction, cerebral vascular malformation or trauma;
15. Severe systemic diseases;
16. Severe dyskinesia or frequent "OFF" or "ON" states
17. Severe infectious diseases (eg HIV, HCV, HBV, syphilis positive)
18. Not suitable to participate in this clinical trial assessed by other physicians
Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT

This is a single-center prospective, non-randomized controlled clinical study in China using CliniMACS TCRα/β+ cell depleted stem cell haploidentical donors versus conventional Beijing protocol for haploidentical hematopoietic stem cell transplantation in children.

1:1 non-randomized controlled clinical study in single center using CliniMACS TCRα/β+ cell depleted stem cell versus conventional Beijing protocol for haploidentical hematopoietic stem cell transplant. The purpose of this study is to obtain 30% decrease grade II-IV aGVHD and better qulity of life for TCRα/β+ cell depleted haploidentical stem cell transplantaion.

Eligibility Criteria:
Inclusion Criteria:

* Age 8 weeks to 18 years
* Children who meet the indicators haploidentical hematopoietic cell transplantation
* No HLA ≥ 9/10 donor or not suitable for this type of donor due to illness
* Informed consent must be signed (by the patient or legal representative)

Exclusion Criteria:

* Liver function abnormalities with bilirubin \>2 mg/dL and elevation of transaminases higher than 400 U/L
* Chronic active viral hepatitis
* Ejection fraction \<50%
* Respiratory failure necessitating supplemental oxygen
* Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study
* Patients unwilling or unable to comply with the protocol or unable to give informed consent
* Concurrent severe or uncontrolled infection
Vit D3 and Omega 3 in Chemo Induced Neuropathy

The purpose of this study is to determine whether administration of mammalian Omega 3 FA(fatty acid) with Vitamin D3 supplements would lower or prevent the risk of neuropathy due to chemotherapy.

The primary objective of this study is to evaluate the impact of mammalian oil Omega 3 FA with Vitamin D3 supplementation on resolution or prevention of Taxanes or Platinum induced peripheral neuropathy compared with placebo. Patients will be allocated to receive the Omega 3 FA \& Vitamin D3 supplements or placebo for 6 months. Approximately 600 patients in total will be enrolled in the 2 study arms. The evaluation of neuropathy will be accomplished by electromyography (EMG), Total neuropathy score(TNS), Brief pain inventory (BFI) and the 11-item FACT/GOG-Ntx, version 4 questionnaire (a subscale validated to assess neuropathy due to chemotherapy). In addition, other validated functional measures such as "Time to button a six hole shirt" and "50 ft walk speed test" will be used to test patients physical limitations imposed by peripheral neuropathy. All our patients will undergo an EMG at their first visit, in 3 months and after 6months. Previously mentioned functional measures will also be completed at the patients' first visit, in 3 months and after 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Will be receiving chemotherapy(Platinums and/or Taxanes) in the following 2 weeks.
* Histologically confirmed diagnosis of cancer
* ECOG 0 to 2

Exclusion Criteria:

* Prior chemotherapy treatment
* Pre-existing peripheral PN due to DM,HIV, alcohol abuse, thyroid dysfunction and hereditary PN associated disorders.
* Taking any nutritional supplement( fish oil, vitamins and minerals) at least there months before enrollment.
Prediction of Delayed Toxic Cardiomyopathy in Children

Longitudinal analysis of myocardial function using "Speckle Tracking Echocardiography" STE analysis and prediction of delayed toxic induced cardiomyopathy in young patients who received anthracycline therapy in childhood.

Anthracycline therapy may have short-, medium- or long-term cardiac toxicity that impacts patient's life. The main recognized risk factors for delayed cardiotoxicity are cumulative anthracycline dose, female gender, association with mediastinal radiotherapy and young age at administration. Prediction of delayed cardiotoxicity in children population is still challenging.

The "Speckle Tracking Echocardiography" (STE) method, an innovative echocardiographic technique, analyses the myocardial displacement of natural acoustic markers via a software. The objective of the study is to analyze, in young patients who received anthracycline therapy in childhood, 5-years after their inclusion in the "Speckle Anthra" study and first STE results, the evolution of myocardial function using STE method.

Eligibility Criteria:
ANTHRA GROUP

Inclusion Criteria:

* Patients who were treated with anthracyclines for malignant disease between the ages of 0 and 18
* Patient aged 11 to 27 years
* Included in the "SpeckleAnthra" Study (NCT02893787)
* Discontinued chemotherapy for more than 6 years
* Patient in remission of malignant disease
* Enrolled in a social security plan
* Written informed consent from at least one legal representative for the minor patient/ Written informed consent for patients of legal age

Exclusion Criteria:

* Onset of active malignancy or recurrence of malignancy after the "Speckle Anthra" study that required resumption of chemotherapy or mediastinal radiotherapy.
* Chronic cardiac, pulmonary or muscular pathology of etiology other than secondary to anthracycline therapy
* For adult patients: subject under guardianship or curators

CONTROL GROUP

Inclusion Criteria:

* Control patient included in the "Speckle Control" study (NCT02056925)
* Had a cardiological consultation with echocardiography performed for a banal reason (heart murmur test, cardiological symptoms) and whose result was normal
* No chronic disease or long-term drug treatment

Exclusion Criteria:

* Refusal to participate in the study by the patient and/or parents or legal guardian after receipt of the study's information and non-objection note.
EpiFaith CV for Central Venous Catheterization

EpiFaith CV provides automatic aspiration and detection of arterial pressure as an alternative to manometry in central venous catheterization. The aim of the study is to evaluate if it may reduce operation time compared with conventional syringe.

Central venous catheterization (CVC) is crucial in modern perioperative and intensive care. Keeping constant and stable negative pressure while advancing the needle had been issue for beginners. Recently, EpiFaith CV provides a new solution for CVC, which facilitates syringe control and precision during assessing vessels. It provides steady aspiration and detection of arterial pressure as an alternative to manometry without the need to disconnect nor more connections. The aim of the study is to evaluate if it may reduce operation time compared with conventional syringe.

Eligibility Criteria:
Inclusion Criteria (for participants):

* 18 years old and above
* Surgical patients who need to have a central venous catheter placed
* Informed and agree to participate in the study

Inclusion Criteria (for conducting physicians):

* Physicians with \>100 central venous catheter placement experience, including attending physicians and senior residents

Exclusion Criteria (for participants):

* Patient refusal
* Puncture site skin lesions
* Uncorrected coagulation disorder
* Hemodynamic instability
* Not informed and consented to participate in research

Exclusion Criteria (for conducting physicians):

* Not informed and consented to participate in research
A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis.

The study will consist of a primary study phase (Visit 1 (baseline) to Visit 2 (Day 6-12)) and a follow-up phase (Visit 2 to Visit 3 (7-12 days post Visit 2)). During the primary phase patients will be randomly assigned in a 1:1 ratio to either Solosec or placebo. Patients will return to the clinic for the "test of cure" (TOC) visit to be conducted on Days 6-12 (Visit 2).

To ensure all patients receive treatment and to maintain the double-blind, after completion of the primary phase, patients will receive the opposite treatment , (placebo patients will receive Solosec and vice versa). Patients with V2 cultures that are subsequently positive for T. vaginalis will return to the clinic for Visit 3 (V3) assessments and investigator assessment of need for additional therapy (an additional Visit 4 may be scheduled at the investigator's discretion if culture at V3 is positive).

Summary of results includes data reported during the primary phase of the study \[Visit 1 (baseline) to Visit 2/TOC (Day 6-12)\]

Eligibility Criteria:
Inclusion Criteria:

* adult female or post-menarche adolescent girl ≥12 years of age in general good health
* Have a diagnosis of trichomoniasis at the screening visit as determined by one of the following:

  * positive T. vaginalis NAAT test within 30 days of screening for which treatment has not been initiated.
  * positive OSOM® rapid test.
  * positive wet mount assessment.
* Agree to abstain from vaginal intercourse until the final study visit
* Agree not to have any vaginal penetration or use of any vaginal products for the duration of the study

Exclusion Criteria:

* Are pregnant, lactating, or planning to become pregnant during the study.
* Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including symptomatic vulvovaginal candidiasis, chlamydia, gonorrhea, or an active genital herpes outbreak
* Are suspected clinically of having an acute urinary tract infection.
* Have active genital lesions, including primary syphilitic chancres and herpes simplex virus lesions, or other vaginal or vulvar conditions which could confound the interpretation of the clinical response, as determined by the Investigator (patients with genital warts may be enrolled).
* Have received systemic antibacterial therapy or topical antimicrobial/antifungal/ immunomodulatory therapies in the genital area (vagina, vulva and surrounding soft tissue), within 14 days prior to the Baseline Visit (Day 1).
Contrast-Enhanced Ultrasound vs Conventional US-guided Percutaneous Needle Biopsy for Pancreatic Diseases: Prospective Multicenter Randomized Controlled Trial

According to previous studies, contrast-enhanced ultrasound (CEUS) -guided Core Biopsy(GB) could improve the diagnosis of biopsy in liver and other superficial mass compared to conventional US-GB. The purpose of this randomized trial is to estimate whether CEUS-GB achieve excellent diagnostic value to conventional US-GB in percutaneous biopsy for pancreatic diseases.

The patients with pancreatic diseases who need receive percutaneous biopsy were randomized with 1:1 ratio into undergo CEUS-GB group and conventional US-GB group.The aims include:

Comparison the diagnostic accuracy rate between CEUS and US group. Comparison the diagnostic specificity, sensitivity and complication rate between CEUS and US group.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years, WHO/ECOG scores \<2;
* Radiographic examination reveal focal pancreatic lesions;
* No history of local treatment for pancreatic lesions, systemic chemotherapy, targeting, immunotherapy, etc;
* Normal organ function, including the following criteria:

  1. Routine blood test: Hb≥80 g/L; PLT≥50×109/L;
  2. Coagulation function test: PT\<20s.

Exclusion Criteria:

* The lesions could not be shown by ultrasound and contrast-enhanced ultrasound;
* Allergic to ultrasound contrast agent;
* Cardiovascular and cerebrovascular diseases, liver, kidney and lung failure with significant clinical symptoms;
* History of unexplained bleeding, severe anemia, bleeding tendency or uncorrected coagulopathy;
* Combined with active infection;
* Massive ascites;
* Patients or family members do not agree to enter the study;
* Pregnant or lactating women;
* The investigator considers that there are any other factors that may be inappropriate for inclusion or affect the subject's participation in the study.
Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions

The purpose of this study is to identify microbial signatures associated with remission and recurrence of idiopathic malodor and PATM conditions.

Human odorprints, mostly owing to the microbiome, have proven their value as biomarkers of health and environmental exposures. In recent years, microbial networks responsible for localized malodors such as halitosis or axillary odor have been mapped by using next generation sequencing approaches. Intestinal microbes responsible for psychologically debilitating systemic malodor (whole-body and extraoral halitosis), however, remain to be identified. Even a relatively straightforward disorder of choline metabolism trimethylaminuria (TMAU) is thought to exhibit complex host-gene microbiome interactions and has not been sufficiently studied.

Proposed controlled pilot study aims to explore the dynamics of microbial communities in remission and flare-up periods. Better knowledge of the important aspects of disease fluctuation should enhance patient care and, combined with our prior data, will help to develop new therapies and treatments.

Eligibility Criteria:
Inclusion Criteria:

* idiopathic malodor or PATM symptoms experienced over a period of several months or years
* able to read and understand the study information
* willing and able to comply with questionnaires, nutritional recommendations, and other study procedures

Exclusion Criteria:

* consistent inability to communicate and process things related to their symptoms
* consistent inability to distinguish physical symptoms from pure emotional reactions
* lack of motivation to start feeling better
Laryngeal Mask Airway for Adenoidectomies (LMAA)

The current study retrospectively assesses laryngeal mask airway use during pediatric adenoidectomies in terms of patient safety, comfort, complications and surgeon satisfaction levels.


Eligibility Criteria:
Inclusion Criteria:

* 1-16 years of age
* ASA I-II
* Scheduled for elective adenoidectomy under general anesthesia with F-LMA between June 2012 and November 2015.

Exclusion Criteria:

* Emergency
* Extreme obesity
* Sign of clinical significant infection.
Glycemic Metrics and Patterns in People With and Without Prediabetes

The FreeStyle Libre 3 Continuous Glucose Monitoring (FSL3) System is used to characterize the glycemic profiles of people with and without a prediabetes diagnosis.

This is a non-pivotal, non-randomized, multi-center, prospective, non-significant risk to evaluate the glycemic profiles of people with and without a prediabetes diagnosis using continuous glucose monitoring. Up to 2000 subjects will be enrolled in up to 20 sites. Approximately 50% of evaluable subjects will have a prediabetes diagnosis.

Eligibility Criteria:
Inclusion Criteria:

* Subject must be at least 18 years of age.
* Subject must be willing and able to provide written signed and dated informed consent.

Exclusion Criteria:

* Subject has a diagnosis of type 1 diabetes, type 2 diabetes, or gestational diabetes.
* Subject is known to be currently practicing a low-carbohydrate or ketogenic diet at the time of enrollment.
* Subject is known to be pregnant at the time of enrollment.
* Subject has known allergy to medical grade adhesive, isopropyl alcohol and/or ethyl alcohol used to disinfect skin.
* Subject is currently on any form of treatment indicated for the treatment of diabetes.
* Subject is currently on any form of medication indicated for weight loss.
Pregnancy Outcome Following Global Fibroid Ablation Using the Acessa™ System

Prospective, interventional, single-center, longitudinal, single-arm pilot study to evaluate pregnancies following the Acessa™ treatment of uterine myomas in women who desire future childbearing


Eligibility Criteria:
Inclusion Criteria:

1. Are premenopausal and aged 18 to 40 years.
2. Have already consented to have their fibroids treated with the Acessa™ procedure.
3. Desire pregnancy within two years following Acessa™ treatment
4. Have a normal endometrial cavity as delineated by sonohysterogram within 6 months prior to treatment.
5. Have a uterine size relating to ≤14 weeks of pregnancy, as determined by palpatory pelvic exam.
6. Have fibroids identified by transvaginal ultrasound with:

   1. ≤6 (six) fibroids of ≤5 cm at the major diameter
   2. a total uterine volume of no greater than 300 cc
7. Patients with type 2 fibroids are acceptable for inclusion.
8. Are current in their screening for cervical cancer precursors (i.e. PAP 1 or 2).
9. Are capable of providing informed consent.
10. Are willing and able to comply with all study tests, procedures, and assessment tools during screening and up to 3 years post treatment.
11. Are able to pass a pre-operative health exam (ASA I-III).
12. Patients who are currently undergoing fertility treatments (e.g. Clomid, IVF, etc.) or who are planning such treatments may be enrolled in the study.

Exclusion Criteria:

1. Have contraindications for laparoscopic surgery and/or general anesthesia.
2. Have cervical myomas or Type 0 or Type 1 myomas. Type 0 and Type 1 myomas are excluded as these are generally accessible to hysteroscopic approaches. Cervical myomas are difficult to treat and present a greater risk of bladder or urethral injury.
3. Have one or more Type 0 (completely intracavitary) or Type 1 resectable submucous fibroids.
4. Have known or suspected abdominal adhesions which are expected to complicate laparoscopic surgery.
5. Have known or suspected untreated intra-uterine adhesions or uterine septum.
6. Have previously undergone endometrial ablation, uterine artery embolization, or uterine artery ligation/occlusion, high-intensity focused ultrasound, laparoscopic, hysteroscopic or abdominal myomectomy, or any other uterine-preserving technique for reduction of menstrual bleeding.
7. Subjects taking platelet-inhibiting drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and clopidogrel
8. Are pregnant or lactating.
9. Have known or suspected severe endometriosis.
10. Have known or suspected adenomyosis.
11. Have active or history of pelvic inflammatory disease.
12. Have a history of or evidence of gynecologic malignancy or pre-malignancy within the past five years.
13. Have had pelvic radiation.
14. Have a persistent and undiagnosed complex adnexal mass.Are unable to give informed consent.
15. In the medical judgment of the investigator should not participate in the study.